<DOC>
	<DOCNO>NCT01261065</DOCNO>
	<brief_summary>The overall hypothesis application improvement LV ejection performance follow treatment betablockers due , least part , improvement intrinsic myocardial contractility .</brief_summary>
	<brief_title>Mechanisms Improvement With Beta-Blocker Treatment Heart Failure</brief_title>
	<detailed_description>The immediate specific objective application two-fold : ( 1 ) determine whether observed improvement LV ejection performance due alteration intrinsic cardiac myocardial contractility ( 2 ) determine whether change LV contractile reserve follow infusion intravenous milrinone use predict salutary response beta-blockers . The immediate specific objective proposal address follow two Specific Aims : In Specific Aim 1 , determine whether observed improvement LV ejection fraction follow treatment beta-blockers due change intrinsic myocardial contractility , oppose change LV remodeling ( i.e . reduction LV volume ) change LV load condition . Changes LV function evaluate use proven index , one ejection phase index : relation end-systolic stress ( ESS ) mean velocity fiber shortening ( VCF ) , consider relatively load independent measure contractility . Changes LV structure evaluate use echocardiography . In Specific Aim 2 , determine whether salutary response beta-blockers predict measure `` contractile reserve '' , define change contractility determine relation mean velocity fiber shortening ( VCF ) end-systolic stress ( ESS ) response intravenous milrinone infusion cardiac catheterization lab prior institution beta-blockade . The response treatment beta-blockers assess measurement LV ejection fraction LV end-diastolic volume echocardiography 6 month treatment beta-blockers , measurement correlate respective change contractile reserve measurement baseline .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>1 . Patients 18 year age old . 2 . Man nonpregnant woman ( woman postmenopausal , surgically sterile practice acceptable method contraception ) 3 . Patients dilate nonischemic cardiomyopathy LVEF &lt; 35 % NYHA Class IIIIVa heart failure 4 . Patients standard stable medical therapy Ace inhibitor ( hydralazine nitrate Angiotensin II Receptor blocker Aceintolerant ) , diuretic digoxin least 1 month prior enrollment study . 5 . Heart failure symptom present least 3 month 6 . Written inform consent 1 . Ischemic heart disease document cardiac catheterization coronary obstructive lesion &gt; 50 % stenosis , history myocardial infarction , coronary artery bypass surgery , percutaneous coronary angioplasty stenting 2 . Uncorrected primary valvular disease , obstructive restrictive cardiomyopathy . 3 . Systolic blood pressure &gt; 170 &lt; 85 mm Hg diastolic blood pressure &gt; 100 mm Hg ; heart rate &lt; 50 bpm . 4 . Sick sinus syndrome advanced heart block ( unless treat pacemaker ) , symptomatic sustain ventricular tachycardia control antiarrhythmic drug implantable defibrillator 5 . Cor pulmonale , obstructive pulmonary disease require oral bronchodilator steroid therapy 6 . Active malignancy , systemic terminal disease would limit physical function survival trial 7 . Active know drug alcohol dependence factor interfere study conduct interpretation result . 8 . Clinically important hepatic renal disease ; condition heart failure could limit survival 9 . Platelet count &lt; 100 000 mm3 white blood cell count &lt; 3000 mm3 , INR ( international normalize ratio ) &gt; 1.7 10 . Current treatment betablocker , betaagonist , verapamil , chronic cyclic continuous inotropic therapy , use investigational drug within 30 day entry challenge phase 11 . History drug sensitivity adverse reaction betablockers 12 . Unwillingness cooperate give write informed consent , pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>beta blocker</keyword>
	<keyword>heart failure</keyword>
	<keyword>contractility</keyword>
	<keyword>remodel</keyword>
</DOC>